Eamonn Hobbs
Fondatore presso ImmunSYS, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Douglas G. Watson | M | 79 |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | 15 anni |
Charles Link | M | 64 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | 4 anni |
Agustin Gago | M | 64 |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | 21 anni |
Marlene Wright Barton | F | - |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | 6 anni |
Howard Donnelly | M | 63 | 20 anni | |
Carrie Manner | F | 50 | 2 anni | |
Mara Aspinall | F | 61 | 7 anni | |
Nancy Gagliano | M | 64 | 3 anni | |
Stephen Trowbridge | M | 49 | 16 anni | |
Christopher Davey | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | 18 anni |
Roger Hatfield | M | 78 |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Igor Keselman | M | - |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. | - |
Lelio Marmora | M | 57 | 4 anni | |
John Burns | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Wesley Johnson | M | 65 | 17 anni | |
Stefano Taucer | M | - | 2 anni | |
Ann Marie Cannon | F | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Jim Datin | M | 61 | 5 anni | |
David Shulkin | M | 64 | 4 anni | |
Jeffrey L. Cleland | M | 59 |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
Joseph C. Maroon | M | 83 |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
Mark A. Saab | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | 18 anni |
Norman Schwartz | M | 74 |
ImmunSYS, Inc.
ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
Zachary Wert | M | - | 2 anni | |
John Kirwan | M | - |
Hobbs Medical Ventures, LLC
Hobbs Medical Ventures, LLC Miscellaneous Commercial ServicesCommercial Services Hobbs Medical Ventures, LLC provides consulting services for the pharmaceutical industry. The private company is based in New York, NY. The company was founded by Eamonn P. Hobbs. | 2 anni |
Kenneth McGrath | M | 52 | 2 anni | |
Leonard Mermel | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Jeffrey Hoggard | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
James O'Reilly | M | - |
Harmonic Medical, Inc.
Harmonic Medical, Inc. Medical SpecialtiesHealth Technology Harmonic Medical, Inc. develops non-invasive surgery treatment for uterine fibroids. It also treats broad range of cancer treatment such as bone metastases, metastic liver cancer, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and kidney cancer. The company is headquartered in Toronto, Canada. | 11 anni |
Johnny John | M | 60 | 12 anni | |
Micheal Kelly | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Paul T. Kostecki | M | 74 |
University of Massachusetts
| 44 anni |
Trace Custer | F | - | 2 anni | |
David A. Rappaport | M | - | 6 anni | |
Gregory Champion | M | 69 |
Syncromune, Inc.
Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. | - |
Mick McEnroe | M | - |
Marvao Medical Devices Ltd.
Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Peter J. Graham | M | 57 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 24 anni |
Stephen Tang | M | 63 | 11 anni | |
D. Joseph Gersuk | M | 74 | 6 anni | |
Ronald Spair | M | 58 | 17 anni | |
William M. Appling | M | 61 |
North American Instrument Corp.
| 6 anni |
Jennifer Simpson | M | 55 | 8 anni | |
Scott Gleason | M | 45 | 2 anni | |
Keith David Hartt | M | 63 |
University of Massachusetts
| 14 anni |
Jack E. Jerrett | M | 65 | 21 anni | |
Agnieszka Gallagher | F | 51 | 1 anni | |
Richard Taney | M | 68 | 4 anni | |
Johannes Keltjens | M | 67 | 2 anni | |
David McDonald | M | 63 | 5 anni | |
Barbra Keck | F | 46 | 11 anni | |
John Purpura | M | 62 | 15 anni | |
Graham Miao | M | 60 | 3 anni | |
Kaushik J. Dave | M | 63 | 5 anni | |
Michael Celano | M | 65 | 16 anni | |
Kin Yip Leung | M | 63 | 3 anni | |
Paul Wotton | M | 63 | 10 anni | |
Douglas Michels | M | 66 | 14 anni | |
Roger Stoll | M | 81 | 16 anni | |
Jennifer Stacey | F | 59 | 1 anni | |
Robert P. Roche | M | 68 | 9 anni | |
Marvin Samson | M | 82 | 7 anni | |
Ronny Lancaster | M | 72 | 19 anni | |
Donald G. Coffey | M | 69 |
University of Massachusetts
| 6 anni |
Michael S. Sharp | M | - | 3 anni | |
John J. Howarth | M | - | 8 anni | |
Krishna Kandarpa | M | 73 |
Society of Interventional Radiology
Society of Interventional Radiology Miscellaneous Commercial ServicesCommercial Services The Society of Interventional Radiology is a national organization based in Fairfax, VA, consisting of physicians, scientists, and allied health professionals. The company is dedicated to improving public health through disease management and minimally invasive, image-guided therapeutic interventions. | 10 anni |
Daniel Moore | M | 63 |
The Medical Device Manufacturers Association
The Medical Device Manufacturers Association Miscellaneous Commercial ServicesCommercial Services The Medical Device Manufacturers Association operates as a trade association. The private company is based in Washington. The American company was founded by Thomas C. Thompson. | 7 anni |
Anthony Zezzo | M | 70 | 9 anni | |
Anne Michelle Whitaker | F | 56 | 2 anni | |
Akbar Moawalla | M | - |
University of Massachusetts
| 6 anni |
Jonathan S. Jaffe | M | - | 9 anni | |
Cuneyt Oge | M | - |
University of Massachusetts
| 6 anni |
Aradhana Sarin | M | 50 | - | |
Steven H. Gardner | M | - |
University of Massachusetts
| 6 anni |
Joseph G. Gerardi | M | 62 | - | |
Jeffrey G. Gold | M | 76 | 22 anni | |
Roger L. Pringle | M | 83 | 17 anni | |
Dennis Meteny | M | 70 | 20 anni | |
Charles W. Patrick | M | 69 | 14 anni | |
Arthur Rosenthal | M | 77 |
Cappella, Inc.
Cappella, Inc. Pharmaceuticals: MajorHealth Technology Cappella, Inc. operates as a medical device company, which develops novel solutions for the treatment of complex coronary artery disease (CAD) and specifically bifurcation vascular disease. The company was founded by Antonio Columbo and Ascher Shmulewitz in 2004 and is headquartered in Boston, MA. | 2 anni |
Steven R. LaPorte | M | 73 | - | |
Anastasios Konidaris | M | 57 | 2 anni | |
Vincent A. Bucci | M | 69 | 7 anni | |
Howard S. Stern | M | 93 | 17 anni | |
Robert Ladd | M | 65 | 6 anni | |
David P. Meyers | M | 60 |
E-Z-EM, Inc.
E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. | 12 anni |
Laura Brege | F | 66 | 2 anni | |
Roberto Cuca | M | 57 | 3 anni | |
Harold C. Mapes | M | 64 | 21 anni | |
Rick Scafidi | M | - |
University of Massachusetts
| 4 anni |
Dario N. R. Carrara | M | 60 | 15 anni | |
Michael Joseph Carne | M | - |
University of Massachusetts
| 5 anni |
David Laird Smith | M | - |
University of Massachusetts
| 4 anni |
Rudolph F. Crew | M | 73 |
University of Massachusetts
| 3 anni |
Jerrold L. Sklar | M | - |
University of Massachusetts
| 4 anni |
Charles H. Steedman | M | - |
University of Massachusetts
| 4 anni |
Karen Bailey | F | - |
University of Massachusetts
| 4 anni |
Lewis Evangelidis | M | - |
University of Massachusetts
| 4 anni |
Steve Chipman | M | - |
University of Massachusetts
| 4 anni |
Mary Thistle | F | 64 |
University of Massachusetts
| 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 89 | 89.00% |
Irlanda | 10 | 10.00% |
Canada | 1 | 1.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Eamonn Hobbs
- Contatti personali